Borderline Resectable Pancreatic Cancer: Gemcitabine/Docetaxel and Oxaliplatin Based Chemo/RT

Completed · Phase 2

Conditions studied: Pancreatic Cancer

In brief

This study is being conducted to find out what effects (good and bad) that a combination of treatment with chemotherapy, radiation therapy and surgery has on you and your pancreatic cancer. The chemotherapy drugs to be used: Gemcitabine, Docetaxel, Oxaliplatin, 5-FU and alpha-interferon. The goal is to decrease the size of the tumor, so that removal by surgery can be performed. Current treatments for this stage of pancreas cancer offer less than ideal results, with little opportunity for treatment with curative intent.

Key facts

Study ID

NCT00761241

Run by

Benaroya Research Institute

People needed

40

Starts

2008-09-01

Expected to finish

2010-04-01

Last updated by the study team

2010-05-26

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Biopsy proven adenocarcinoma of the pancreas
• Tumor must be radiographically bidimensional by abdominal/pelvic CT
• Cancer must be locally advanced and not considered immediately treated by standard surgical procedure
• No prior therapy for pancreas cancer

You may not qualify if…

• Women who are pregnant or lactating
• Subjects who have received prior external beam radiation to the abdomen or pelvis
• Subjects receiving chronic immunosuppressive therapy (prednisone, methotrexate)

Where it is running

• Virginia Mason Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.